Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Target Price from Brokerages

Shares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $12.80.

A number of equities research analysts have recently issued reports on IMRX shares. Needham & Company LLC reissued a "buy" rating and issued a $15.00 target price on shares of Immuneering in a research report on Thursday, November 14th. Chardan Capital reiterated a "buy" rating and issued a $13.00 target price on shares of Immuneering in a report on Wednesday.

Immuneering Stock Performance

IMRX stock remained flat at $2.04 during mid-day trading on Wednesday. 176,098 shares of the company's stock traded hands, compared to its average volume of 2,234,157. Immuneering has a 52-week low of $1.00 and a 52-week high of $8.89. The company has a market cap of $63.34 million, a price-to-earnings ratio of -1.04 and a beta of -0.40. The business has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $1.62.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. purchased a new position in Immuneering in the 3rd quarter worth $25,000. Corsair Capital Management L.P. bought a new position in shares of Immuneering during the third quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Immuneering during the second quarter valued at about $44,000. XTX Topco Ltd increased its position in shares of Immuneering by 37.3% during the second quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock valued at $44,000 after buying an additional 9,274 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in Immuneering in the second quarter worth about $67,000. Institutional investors own 67.65% of the company's stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.